Core Viewpoint - Lianhuan Pharmaceutical's stock experienced a significant drop, reaching the daily limit down on July 15, indicating potential market concerns regarding the company's performance and investor sentiment [1]. Company Overview - Lianhuan Pharmaceutical Co., Ltd. was established in December 1999, originating from Yangzhou Pharmaceutical Factory founded in 1958, and is recognized as a national high-tech enterprise engaged in research, production, and sales [1]. Shareholder Activity - Two funds under China Merchants Fund have entered the top ten shareholders of Lianhuan Pharmaceutical, holding a combined stake of 0.88%. Specifically, the China Merchants Quantitative Selected Stock A fund increased its holdings in the first quarter of this year, while the China Merchants Growth Quantitative Stock Selection A fund made a new entry [1]. - The China Merchants Quantitative Selected Stock A fund has achieved a year-to-date return of 20.03%, ranking 138 out of 992 in its category, while the China Merchants Growth Quantitative Stock Selection A fund has a year-to-date return of 15.45%, ranking 229 out of 992 [1]. Fund Performance Comparison - The performance of the China Merchants Quantitative Selected Stock A fund over various periods is as follows: - 1-week increase: 3.04% - 1-month increase: 8.72% - 3-month increase: 18.07% - 6-month increase: 21.12% - Year-to-date increase: 20.03% [2]. - In comparison, the average return of similar funds and the CSI 300 index shows lower performance, indicating that the China Merchants Quantitative Selected Stock A fund is outperforming its peers [2]. Fund Manager Profile - Wang Ping, the fund manager for both the China Merchants Quantitative Selected Stock A and the China Merchants Growth Quantitative Stock Selection A funds, has extensive experience in investment risk management and quantitative analysis, having joined China Merchants Fund in 2006 [5][6].

证券代码：600513 证券简称：联环药业 公告编号：2025-045 江苏联环药业股份有限公司 第九届董事会第十一次临时会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召集与召开情况 江苏联环药业股份有限公司（以下简称"公司"或"联环药业"）第九届董 事会第十一次临时会议于 2025 年 7 月 15 日以通讯方式召开，本次会议通知于 2025 年 7 月 10 日以电子邮件形式发出。会议应出席董事 9 名，实际出席董事 9 名，出席会议人数符合《公司章程》的规定。本次董事会由公司董事长钱振华先 生主持，会议经过了适当的召集和通知程序，符合《中华人民共和国公司法》等 相关法律、法规及《公司章程》的规定，会议合法有效。 二、董事会会议审议情况 会议就下列议案进行了认真的审议，经与会董事投票表决，通过如下决议： （一）审议通过《关于公司新建出口制剂厂房、新建抗肿瘤合成厂房和抗 肿瘤制剂厂房及生产线的议案》 （表决情况：赞成 9 票，反对 0 票，弃权 0 票） 具体内容详见上海证券交易所网站 www.sse ...

证券代码：600513 证券简称：联环药业 公告编号：2025—046 江苏联环药业股份有限公司 关于公司及全资子公司新建厂房、生产线的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、项目概述 （一）项目的基本情况 江苏联环药业股份有限公司（以下简称"公司"、"联环药业"）及公司全 资子公司扬州制药有限公司（以下简称"扬州制药"）拟规划共出资 30,000.00 万元人民币于公司西南角土地建设三栋厂房，分别为出口制剂厂房、抗肿瘤合成 厂房和抗肿瘤制剂厂房，其中联环药业拟以自筹资金合计 15,000.00 万元人民币 出资建设出口制剂药厂房、抗肿瘤合成厂房和抗肿瘤制剂厂房及生产线，包含抗 肿瘤细胞毒合成生产线(包括精烘包)和抗肿瘤非细胞毒合成生产线(包括精烘 包)；抗肿瘤制剂厂房包含抗肿瘤细胞毒类口服药物生产线、抗肿瘤非细胞毒类 口服药物生产线，扬州制药拟以自有资金合计 15,000.00 万元人民币出资建设出 口制剂药生产线及配套立体库。厂房内包含激素类小容量注射剂及冻干生产线、 激素类固体制剂生产线、普通小容量注射剂 ...

联环药业：公司及全资子公司拟新建厂房和生产线 总投资3亿元 智通财经7月15日电，联环药业(600513.SH)公告称，公司及全资子公司扬州制药拟规划共出资30,000.00 万元人民币建设三栋厂房，包括出口制剂厂房、抗肿瘤合成厂房和抗肿瘤制剂厂房。其中，联环药业拟 出资15,000.00万元建设相关厂房及生产线，扬州制药拟出资15,000.00万元建设出口制剂药生产线及配套 立体库。项目建设工期预计分别为36个月和24个月，总投资分别为15,000.00万元。项目有助于提升公司 在抗癌治疗领域的布局，增强国内抗癌药物市场的竞争力，并推动公司国际化战略目标的实现。 ...

创新药概念股集体调整， 塞力医疗、 联环药业跌停， 常山药业、 哈三联、 润都股份、 泓博医药、 北 陆药业、 昂利康、 舒泰神等跌超5%。 ...

Group 1 - The Central Committee of the Communist Party of China has issued opinions to strengthen judicial work in the new era, emphasizing severe punishment for financial crimes such as market manipulation, insider trading, illegal fundraising, loan fraud, and money laundering [1] - To maintain ample liquidity in the banking system, the People's Bank of China will conduct a 1.4 trillion yuan reverse repurchase operation using a fixed quantity, interest rate bidding, and multiple price levels starting from July 15, 2025 [1] - The Deputy Governor of the Central Bank, Zou Lan, stated that structural monetary policy tools will focus on supporting technological innovation and boosting consumption, with an improvement in the misalignment of monetary policy cycles between China and the US expected in the second half of the year, leading to a narrowing of interest rate differentials [1] Group 2 - Ganfeng Lithium expects a net loss of 300 million to 550 million yuan for the first half of the year, while Tianqi Lithium anticipates a net profit of 0 to 155 million yuan, marking a turnaround from losses [2] - Xiangyang Bearing is projected to have a net loss of 13 million yuan for the half-year period, and Jingyuntong expects a net loss of 165 million to 225 million yuan [2] - Greenland Holdings anticipates a net loss of 3 billion to 3.5 billion yuan for the first half of the year, while Zhongyan Chemical reports an 88% year-on-year decline in net profit [2] - Tongwei Co. expects a net loss of 4.9 billion to 5.2 billion yuan, and JA Solar anticipates a net loss of 2.5 billion to 3 billion yuan for the first half of the year [2] - Longi Green Energy expects a net loss of 2.4 billion to 2.8 billion yuan, showing a reduction in losses compared to previous periods [2] - Lianhuan Pharmaceutical anticipates a net loss of 38 million to 45 million yuan for the first half of the year [2]

证券代码：600513 证券简称：联环药业 公告编号：2025—044 江苏联环药业股份有限公司 2025 年半年度业绩预告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 业绩预告的具体适用情形：净利润为负值。 江苏联环药业股份有限公司（以下简称"公司"）财务部门初步测算，预 计公司 2025 年半年度实现归属于上市公司股东的净利润区间为-4,500.00 万元 人民币至-3,800.00 万元人民币，与上年同期相比将减少 10,088.79 万元人民币 到 10,788.79 万元人民币，业绩由盈转亏。 本次业绩预告数据未经审计，仅为初步核算数据，具体准确的财务数据以 公司正式披露的 2025 年半年度报告为准，敬请广大投资者注意投资风险。 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 6 月 30 日 （二）业绩预告情况 1、经财务部门初步测算，预计公司 2025 年上半年度归属于上市公司股东的 净利润区间为-4,500.00 万元人民币至-3,800.00 万元人民币，与上年同期相比 ...

联环药业（600513）公告，预计2025年半年度归属于上市公司股东的净利润为-4500万元至-3800万元， 与上年同期的6288.79万元相比减少1.01亿元到1.08亿元，业绩由盈转亏。预计2025年半年度归属于上市 公司股东的扣除非经常性损益的净利润为1850万元至2200万元，与上年同期的6107.74万元相比减少 3907.74万元到4257.74万元，同比减少63.98%到69.71%。本次业绩预告数据未经审计，具体准确的财务 数据以公司正式披露的2025年半年度报告为准。 ...

Group 1: Stock Performance - Companies like Shangwei New Materials and Lianhuan Pharmaceutical have shown significant stock performance, with Shangwei New Materials achieving a 20.00% increase over four consecutive trading days [2][9][36] - Other notable performers include Greenfield Machinery and Da Yi Long, both of which have seen increases of approximately 10% over two trading days [5][7] - The stock of YN Energy has also performed well, with a 9.95% increase over six trading days, driven by performance and electricity sector dynamics [13] Group 2: Industry Trends - The A-share market has shown an overall improvement in mid-year performance, with a higher rate of positive earnings compared to the previous year, indicating structural investment opportunities [4] - The electric power sector is experiencing a surge in demand, with the national maximum power load reaching a historical high of 1.465 billion kilowatts, reflecting a year-on-year increase of nearly 150 million kilowatts [12] - The rare earth industry is expected to benefit from recovering exports and seasonal supply increases, leading to improved profitability for companies in this sector [15] Group 3: Innovation and Technology - The launch of the national basic medical insurance and commercial health insurance innovation drug directory is set to stimulate growth in the pharmaceutical sector, with companies like Lianhuan Pharmaceutical and Kangchen Pharmaceutical benefiting from this trend [8][9] - The AI industry in Shanghai has shown remarkable growth, with a 29% increase in scale and a 65% rise in profits in the first quarter, indicating a strong demand for AI-related technologies [31] Group 4: Regulatory Developments - The State Council's food safety committee has introduced measures to enhance food safety risk management, which may positively impact companies in the food safety sector [24] - Recent policies promoting the integration of large-scale charging facilities with power grid planning are expected to benefit companies involved in smart grid technologies [25]

Investment Rating - The report indicates a positive outlook for the pharmaceutical and biotechnology sector, with a focus on innovative drug companies [2][3]. Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.82%, outperforming the CSI 300 index (0.82%) and the Wind All A index (1.71%). The market is currently focused on the expectations surrounding semi-annual reports and business development (BD) activities [8][9]. - The launch of the 2025 National Basic Medical Insurance and Commercial Health Insurance innovative drug directory is a significant development. This directory will include high-innovation drugs that provide substantial clinical value and patient benefits, which are not covered by basic medical insurance but recommended for commercial health insurance [3][13]. - The report highlights the importance of the commercial health insurance sector in the payment for innovative drugs, suggesting that the accessibility of high-priced innovative drugs is expected to improve, particularly in the areas of cell and gene therapy [3][13]. Market Weekly Review - The medical research outsourcing sector led the gains with a 9.29% increase, primarily driven by WuXi AppTec's positive semi-annual report announcement. Conversely, offline pharmacies and other biological products experienced declines of -1.29% and -1.55%, respectively [8][9]. - Notable stock performances included Frontier Biotech-U (41.4%), Mediso (38.9%), and Lianhuan Pharmaceutical (38.6%) leading the gains, while ST Unimed (-18.5%), Shenzhou Cell-U (-13.4%), and Shutai Shen (-11.6%) faced significant losses [11][12]. Industry News and Key Company Announcements - The report outlines several key industry events, including the approval of innovative drugs and strategic partnerships among major pharmaceutical companies, which are expected to enhance their market positions and product offerings [13][16][17]. - The report also mentions significant financial forecasts from various companies, indicating strong growth potential in the sector, with some companies projecting net profit increases of over 100% year-on-year [17][18].